ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
ASCO-GI – ALX resurrects evorpacept
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
